Tim Demuth is a seasoned biopharma executive with broad leadership experience in drug development, with a focus in oncology. 

He joined MorphoSys from Pieris Pharmaceuticals, Inc, where he was Chief Medical Officer. Prior to this position, he was Vice President and Head of Global Clinical Development Oncology at Merck KGaA, where he was responsible for the early- and late-stage oncology pipeline of small molecules, antibodies and antibody-drug conjugates, as well as for the end-to-end development strategy for oncology. Previously, he led the Clinical Development Unit of Hematology Biopharma Development at Sandoz AG, a division of Novartis AG. Tim held other leadership roles at Novartis AG, Italfarmaco S.p.A and Merck & Co. He received M.D. and Ph.D. degrees from Johannes-Gutenberg-University, Mainz, Germany and was trained in Mainz and at Ludwig-Maximilian-University, Munich, Germany. He has also served as a Post-Doctoral Fellow at the Translational Genomics Research Institute in Phoenix, Arizona.